Is rosiglitazone a reasonable second or third line agent in the management of Type 2 Diabetes (DM2)?
Strong evidence supports increased cardiovascular risk^ specifically MI^ in Type 2 Diabetes patients receiving rosiglitazone. In the absence of any demonstrated patient oriented benefits^ there is no indication for its use.
*** Original Documents can be found and downloaded using the link provided below ***
Publication Date: 2013-12-3
Last Updated on PCR: 2017-03-31 16:35:43